Literature DB >> 7867565

Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats.

S Thyagarajan1, J Meites, S K Quadri.   

Abstract

The purpose of this study was to investigate the effects of long term treatment with deprenyl, a monoamine oxidase-B inhibitor, on estrous cyclicity, serum PRL, incidence of mammary and pituitary tumors, and monoamine metabolism in the medial basal hypothalamus (MBH) and striatum (ST) of old female rats. Acyclic female Sprague-Dawley rats (15-16 months old) were treated sc with 0, 0.25, or 2.5 mg deprenyl/kg BW.day for more than 8 months. Body weight and food intake were measured every week, and the estrous cycles and development of mammary tumors were monitored throughout the treatment period. At the end of the treatment period, the concentrations of catecholamines, serotonin, and their metabolites in the MBH and ST were determined by HPLC with electrochemical detection. The wet weights of the pituitary, heart, liver, lung, kidney, adrenals, uterus, and ovaries were recorded. Trunk blood was collected for measurement of serum PRL concentrations by RIA. Deprenyl treatment temporarily reestablished estrous cycles in most of the rats. The incidence of pituitary and mammary tumors was markedly reduced in the deprenyl-treated rats compared with that in the saline-treated control rats. Deprenyl had no significant effect on the weights of internal organs. The high dose of deprenyl (2.5 mg/kg) decreased serum PRL concentrations significantly. There were no significant differences in body weight or food intake between the control and deprenyl-treated groups. Deprenyl decreased the concentrations of the monoamine metabolites, dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindoleacetic acid, in both the MBH and ST. It had no effect on the concentrations of norepinephrine and dopamine in the MBH, but significantly increased norepinephrine concentrations in the ST and serotonin concentrations in both the MBH and ST (P < 0.05). It is concluded that deprenyl treatment exerted these effects via suppression of monoamine metabolism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7867565     DOI: 10.1210/endo.136.3.7867565

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  R-deprenyl: pharmacological spectrum of its activity.

Authors:  K Magyar; B Szende; V Jenei; T Tábi; M Pálfi; E Szöko
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

Review 2.  Sympathetic modulation of immunity: relevance to disease.

Authors:  Denise L Bellinger; Brooke A Millar; Sam Perez; Jeff Carter; Carlo Wood; Srinivasan ThyagaRajan; Christine Molinaro; Cheri Lubahn; Dianne Lorton
Journal:  Cell Immunol       Date:  2008-03-04       Impact factor: 4.868

3.  The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model.

Authors:  Gabor Bekesi; Zsolt Tulassay; Gabriella Lengyel; Zsuzsa Schaff; Dezso Szombath; Julia Stark; Istvan Marczell; Peter Nagy-Repas; Ildiko Adler; Elek Dinya; Karoly Racz; Kalman Magyar
Journal:  J Neural Transm (Vienna)       Date:  2011-06-05       Impact factor: 3.575

4.  Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes.

Authors:  Eszter Lajkó; Lívia Polgár; Orsolya Láng; József Lengyel; László Kőhidai; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2011-11-16       Impact factor: 3.575

5.  Increased cell-cell adhesion, a novel effect of R-(-)-deprenyl.

Authors:  V Jenei; K Zor; K Magyar; J Jakus
Journal:  J Neural Transm (Vienna)       Date:  2005-03-23       Impact factor: 3.575

6.  L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors.

Authors:  S ThyagaRajan; S K Quadri
Journal:  Endocrine       Date:  1999-06       Impact factor: 3.633

7.  Trade-off between cancer and aging: what role do other diseases play? Evidence from experimental and human population studies.

Authors:  Anatoli I Yashin; Svetlana V Ukraintseva; Igor V Akushevich; Konstantin G Arbeev; Alexander Kulminski; Lucy Akushevich
Journal:  Mech Ageing Dev       Date:  2008-03-25       Impact factor: 5.432

Review 8.  Role of dopamine in malignant tumor growth.

Authors:  S Basu; P S Dasgupta
Journal:  Endocrine       Date:  2000-06       Impact factor: 3.925

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.